<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7270517\results\search\testTrace\results.xml">
  <result pre="public health issue threatening millions of lives worldwide. Although the" exact="infection" post="is mild in most of the affected individuals, it"/>
  <result pre="this pandemic, and the use of anti-rheumatic drugs in COVID-19" exact="treatment" post="are discussed. Electronic supplementary material The online version of"/>
  <result pre="respiratory syndrome coronavirus 2) from coronoviridae family [1, 2]. The" exact="infection" post="quickly spread over the world. The World Health Organization"/>
  <result pre="the world. The World Health Organization (WHO) officially named this" exact="infection" post="as COVID-19 (coronavirus disease 2019) on February 11th, 2020,"/>
  <result pre="respiratory droplets [3, 4]. Primary prevention strategies such as quarantine," exact="social distancing," post="and hand hygiene are the main methods to prevent"/>
  <result pre="and hand hygiene are the main methods to prevent the" exact="infection" post="since there has been no vaccine or specific antiviral"/>
  <result pre="infection since there has been no vaccine or specific antiviral" exact="treatment" post="yet. SARS-CoV-2 has considerable genetic resemblance (around 80%) with"/>
  <result pre="than the virus titer was related to death in SARS-CoV" exact="infection" post="[16, 17]. The infection is mild in most of"/>
  <result pre="was related to death in SARS-CoV infection [16, 17]. The" exact="infection" post="is mild in most of the affected individuals while"/>
  <result pre="experience a mild form of the disease in case of" exact="infection" post="[4, 23]. In the cohort study, including 72,314 COVID-19"/>
  <result pre="drugs that are currently being used and tested in COVID-19" exact="treatment" post="are mostly the ones used by patients with rheumatic"/>
  <result pre="COVID-19 patients with rheumatic diseases in the literature, and COVID-19" exact="treatment" post="with the drugs used for rheumatic diseases are discussed."/>
  <result pre="underlying rheumatic disease: age, sex, underlying rheumatic disease, age at" exact="diagnosis" post="of the rheumatic disease, features associated with rheumatic disease,"/>
  <result pre="associated with rheumatic disease, other comorbidities, the previous and current" exact="treatment" post="of rheumatic disease, COVID-19-related symptoms, the method for COVID-19"/>
  <result pre="rheumatic disease, COVID-19-related symptoms, the method for COVID-19 diagnosis, COVID-19" exact="treatment" post="and outcome, and features regarding cessation and re-initiation of"/>
  <result pre="arthritis, RA rheumatoid arthritis, RD rheumatic disease, RT-PCR reverse transcriptase" exact="polymerase chain reaction," post="RTX rituximab, SEC secukinumab, SjS SjÃ¶grenâ€™s syndrome, SLE systemic"/>
  <result pre="al. reported that 465 patients with rheumatic diseases had a" exact="diagnosis" post="of COVID-19 based on symptoms or physician diagnosis with"/>
  <result pre="had a diagnosis of COVID-19 based on symptoms or physician" exact="diagnosis" post="with positive laboratory tests [46]. However, no further details"/>
  <result pre="on chronic hydroxychloroquine (HCQ) and seven were on chronic colchicine" exact="treatment" post="[45]. But they did not mention the underlying diseases"/>
  <result pre="results. Some of these confounding factors are population age, ethnicity," exact="testing" post="rates for COVID-19 infection, the stage of the pandemic"/>
  <result pre="each country, income levels, and major policy decisions (such as" exact="quarantine" post="and providing self-protecting equipment like masks). Another limiting factor"/>
  <result pre="al. demonstrated that IgG titers against rubella increased in SARS-CoV-2" exact="infection" post="in some cases, which might suggest a structural homology"/>
  <result pre="unanswered scientific questions There are still no data about the" exact="infection" post="rate and course of COVID-19 in patients with rheumatic"/>
  <result pre="focuses on the immunosuppression caused by the disease itself or" exact="treatment" post="of the disease, a variety of immune dysregulation besides"/>
  <result pre="course and recovered in a couple of days without any" exact="treatment" post="[42]. Previous data suggest that mutations in the main"/>
  <result pre="on the patients we are already treating with an established" exact="diagnosis" post="of a rheumatic disease. In a considerable amount of"/>
  <result pre="or tendency to COVID-19 regarding a specific rheumatic disease or" exact="treatment" post="before solid scientific evidence is obtained. Treatment of COVID-19"/>
  <result pre="considerations for patients with rheumatic diseases The hallmarks of COVID-19" exact="treatment" post="are currently antiviral drugs, drugs interfering with viral entry,"/>
  <result pre="et al. reported that no benefit was associated with lopinavir/ritonavir" exact="treatment" post="beyond standard care [109]. Ongoing trials will provide further"/>
  <result pre="data regarding the efficacy and safety of lopinavir/ritonavir in COVID-19" exact="treatment" post="(e.g., ChiCTR2000029609; NCT04261907). NSAIDs (nonsteroidal anti-inflammatory drugs) NSAIDs (nonsteroidal"/>
  <result pre="practice, NSAIDs are the primary therapeutic options, especially in the" exact="treatment" post="of oligoarticular JIA. Ibuprofen has been reported to increase"/>
  <result pre="[117]. Some studies show beneficial effects of glucocorticoids in the" exact="treatment" post="of coronavirus (SARS and MERS) pneumonia [118â€&quot;120]. On the"/>
  <result pre="more adverse effects with the use of corticosteroids in coronavirus" exact="infection" post="[121]. And most recently, Tsai et al. have demonstrated"/>
  <result pre="recently, Tsai et al. have demonstrated that an early corticosteroid" exact="treatment" post="was associated with significantly increased hospital mortality in adult"/>
  <result pre="ARDS [122]. Regarding COVID-19, Wu et al. demonstrated that methylprednisolone" exact="treatment" post="appeared to decrease the risk of death among patients"/>
  <result pre="mechanisms, it appeared as a candidate for both prophylaxis and" exact="treatment" post="in COVID-19. To assess its prophylactic use, Shah et"/>
  <result pre="patients and 16 controls), Gautret et al. showed that HCQ" exact="treatment" post="was significantly associated with viral load reduction with more"/>
  <result pre="evidence (e.g., NCT04307693, NCT04323631). Currently, HCQ is used in the" exact="treatment" post="of COVID-19 in most countries and for prophylaxis in"/>
  <result pre="of short supplies for patients who need this drug, prophylactic" exact="treatment" post="should not be recommended at this stage. Monti et"/>
  <result pre="(64%) COVID-19 patients with SLE were taking HCQ/chloroquine (CQ) before" exact="infection" post="with SARS-CoV-2 [34]. Moreover, the frequency of hospitalization did"/>
  <result pre="Thus, these drugs should be used with caution in the" exact="treatment" post="of COVID-19. Of note, Saleh et al. reported that"/>
  <result pre="adult rheumatology. But these drugs are currently used in the" exact="treatment" post="of JIA and autoinflammatory interferonopathies [133, 134]. JAK inhibitors"/>
  <result pre="may exert an antiviral effect at the doses used for" exact="treatment" post="in RA [136], emerging as a potential treatment option"/>
  <result pre="used for treatment in RA [136], emerging as a potential" exact="treatment" post="option in COVID-19. JAK inhibitors may be beneficial at"/>
  <result pre="reported an improvement in respiratory and laboratory parameters with tocilizumab" exact="treatment" post="[144]. Moreover, there are a few case reports on"/>
  <result pre="case reports on the successful use of tocilizumab in the" exact="treatment" post="of severe childhood COVID-19 [145, 146]. Based on these"/>
  <result pre="severe childhood COVID-19 [145, 146]. Based on these data, anti-IL-6" exact="treatment" post="is currently the most studied drug in the treatment"/>
  <result pre="anti-IL-6 treatment is currently the most studied drug in the" exact="treatment" post="of COVID-19-associated cytokine storm (NCT04322773, NCT04317092, NCT04320615, NCT04306705, NCT04324073,"/>
  <result pre="a recent retrospective cohort study, Cavalli et al. evaluated anakinra" exact="treatment" post="in COVID-19 [147]. They compared the outcome between 16"/>
  <result pre="the outcome between 16 patients who were on only standard" exact="treatment" post="(HCQ and lopinavir/ritonavir) in addition to mechanic ventilation and"/>
  <result pre="taking high-dose intravenous (IV) anakinra in addition to the standard" exact="treatment" post="and mechanic ventilation. Both overall survival and mechanic ventilation-free"/>
  <result pre="more frequent in the high-dose anakinra group than the standard" exact="treatment" post="group (90% versus 56% and 72% versus 56%, respectively)."/>
  <result pre="a higher level of evidence for the efficacy of this" exact="treatment" post="(NCT04324021, NCT04330638). Anti-IL-1 treatment has indeed been suggested by"/>
  <result pre="evidence for the efficacy of this treatment (NCT04324021, NCT04330638). Anti-IL-1" exact="treatment" post="has indeed been suggested by some pediatric rheumatologists to"/>
  <result pre="been suggested by some pediatric rheumatologists to be the first-line" exact="treatment" post="[73]. There are also ongoing trials for anti-TNF use"/>
  <result pre="cases. Other drugs In severe cases of secondary HLH/MAS, anti-IFN-Î³" exact="treatment" post="is a critical therapeutic option. There is also an"/>
  <result pre="an open-label, phase II trial for colchicine use in COVID-19" exact="treatment" post="[149]. Convalescent plasma treatment Convalescent plasma treatment has emerged"/>
  <result pre="trial for colchicine use in COVID-19 treatment [149]. Convalescent plasma" exact="treatment" post="Convalescent plasma treatment has emerged as a promising option"/>
  <result pre="use in COVID-19 treatment [149]. Convalescent plasma treatment Convalescent plasma" exact="treatment" post="has emerged as a promising option for the control"/>
  <result pre="injury [150]. Considerations for patients with rheumatic diseases regarding their" exact="treatment" post="At the moment, all international rheumatology societies, including ACR"/>
  <result pre="and PReS (Pediatric Rheumatology European Society) recommend continuation of immunosuppressive" exact="treatment" post="in patients with rheumatic diseases. Previous studies on SLE"/>
  <result pre="on drugs that are currently being tested for prophylaxis or" exact="treatment" post="of COVID-19. And it is difficult to predict the"/>
  <result pre="predict the effects of being already on these treatments on" exact="infection" post="rate and severity. As discussed above, there is a"/>
  <result pre="safe site, NSAIDs may not be proposed as a primary" exact="treatment" post="of rheumatic diseases or may be discontinued if they"/>
  <result pre="most of the SLE patients in this study received long-term" exact="treatment" post="with HCQ, having blood concentrations of the drug within"/>
  <result pre="Thus, being on these drugs at the early phase of" exact="infection" post="could be a disadvantage for rheumatology patients. On the"/>
  <result pre="not least, how will our decisions be affected while initiating" exact="treatment" post="for the patients that are newly diagnosed with a"/>
  <result pre="individuals with comorbidities. There are very limited data about the" exact="infection" post="rate and disease course in patients with rheumatic diseases"/>
  <result pre="to infections. Having said that one needs to decide on" exact="treatment" post="on an individual basis, considering personal risk factors. It"/>
  <result pre="scientific evidence and common sense while making decisions about the" exact="treatment" post="of our patients and follow the primary prevention principles"/>
  <result pre="follow the primary prevention principles such as hand hygiene and" exact="social distancing." post="Electronic supplementary material Below is the link to the"/>
  <result pre="patients with severe acute respiratory syndromeJ Virol2007818692870610.1128/JVI.00527-0717537853 12.YeQWangBMaoJThe pathogenesis and" exact="treatment" post="of the `Cytokine Storm' in COVID-19J Infect202010.1016/j.jinf.2020.03.03732474032 13.LiuLWeiQLinQFangJWangHKwokHTangHNishiuraKPengJTanZWuTCheungKWChanKHAlvarezXQinCLacknerAPerlmanSYuenKYChenZAnti-spike IgG"/>
  <result pre="therapeutic toolsVirol Sin202010.1007/s12250-020-00207-432125642 15.ZhangWZhaoYZhangFWangQLiTLiuZWangJQinYZhangXYanXZengXZhangSThe use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
  <result pre="series of 17 patients with systemic lupus erythematosus under long-term" exact="treatment" post="with hydroxychloroquineAnn Rheum Dis202010.1136/annrheumdis-2020-21756632475832 33.MihaiCDobrotaRSchroderMGaraimanAJordanSBeckerMOMaurerBDistlerOCOVID-19 in a patient with"/>
  <result pre="antirheumatic drugsRheumatol Int202010.1007/s00296-020-04584-732314011 36.DamianiGPacificoABragazziNLMalagoliPBiologics increase the risk of SARS- CoV-2" exact="infection" post="and hospitalization, but not ICU admission and death: real-life"/>
  <result pre="data from a large cohort during RED-ZONE declarationDermatol Ther202010.1111/dth.1347532415727 37.DousaKMMalavadeSSFurinJGripshoverBHatszegiMHojatLSaadeESalataRASARS-CoV-2" exact="infection" post="in a patient on chronic hydroxychloroquine therapy: implications for"/>
  <result pre="spondyloarthritis treated with TNF-alpha inhibitor etanerceptAnn Rheum Dis202010.1136/annrheumdis-2020-21736232354772 39.EmmiGBettiolAMattioliISilvestriEDi ScalaGUrbanMLVaglioAPriscoDSARS-CoV-2" exact="infection" post="among patients with systemic autoimmune diseasesAutoimmun Rev202010.1016/j.autrev.2020.10257532376395 40.FavalliEGIngegnoliFCimazRCaporaliRWhat is"/>
  <result pre="of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2" exact="infection" post="and severe COVID-19Ann Rheum Dis202010.1136/annrheumdis-2020-21769032475834 42.MoutsopoulosHMAnti-inflammatory therapy may ameliorate"/>
  <result pre="Wkly Rep20206945846410.15585/mmwr.mm6915e332298251 45.GendelmanOAmitalHBragazziNLWatadAChodickGContinuous hydroxychloroquine or colchicine therapy does not prevent" exact="infection" post="with SARS-CoV-2: insights from a large healthcare database analysisAutoimmun"/>
  <result pre="Xu S, Wong GWK, Chinese Pediatric Novel Coronavirus Study TSARS-CoV-2" exact="infection" post="in childrenN Engl J Med20203821663166510.1056/NEJMc200507332187458 55.RobertsLPandemic brings mass vaccinations"/>
  <result pre="Virol202010.1002/jmv.2580732232980 57.ChenHGuoJWangCLuoFYuXZhangWLiJZhaoDXuDGongQLiaoJYangHHouWZhangYClinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="infectionsClin Microbiol Infect2019251473147810.1016/j.cmi.2019.04.02031055165 61.ArtsRJWMoorlagSNovakovicBLiYWangSYOostingMKumarVXavierRJWijmengaCJoostenLABReuskenCBennCSAabyPKoopmansMPStunnenbergHGvan CrevelRNeteaMGBCG vaccination protects against experimental viral" exact="infection" post="in humans through the induction of cytokines associated with"/>
  <result pre="73.CronRQChathamWWThe rheumatologist's role in COVID-19J Rheumatol202010.3899/jrheum.20033432451354 74.CronRQDaviSMinoiaFRavelliAClinical features and correct" exact="diagnosis" post="of macrophage activation syndromeExpert Rev Clin Immunol2015111043105310.1586/1744666X.2015.105815926082353 75.Rodriguez-MoralesAJCardona-OspinaJAGutierrez-OcampoEVillamizar-PenaRHolguin-RiveraYEscalera-AntezanaJPAlvarado-ArnezLEBonilla-AldanaDKFranco-ParedesCHenao-MartinezAFPaniz-MondolfiALagos-GrisalesGJRamirez-VallejoESuarezJAZambranoLIVillamil-GomezWEBalbin-RamonGJRabaanAAHarapanHDhamaKNishiuraHKataokaHAhmadTSahRClinical, laboratory"/>
  <result pre="IFNopathiesPediatr Res20208774575210.1038/s41390-019-0614-231641281 82.BasatnehRVlahovicTCAddressing the question of dermatologic manifestations of SARS-CoV-2" exact="infection" post="in the lower extremities: a closer look at the"/>
  <result pre="Zhi202041E00610.3760/cma.j.issn.0253-2727.2020.000632220276 85.BatuEDKaradagOTaskiranEZKalyoncuUAksentijevichIAlikasifogluMOzenSA case series of adenosine deaminase 2-deficient patients emphasizing" exact="treatment" post="and genotype-phenotype correlationsJ Rheumatol2015421532153410.3899/jrheum.15002426233953 86.OzenSBatuEDTaskiranEZOzkaraHAUnalSGulerayNErdenAKaradagOGumrukFCetinMSonmezHEBilginerYAyvazDCTezcanIA Monogenic disease with a"/>
  <result pre="103.AuKReedGCurtisJRKremerJMGreenbergJDStrandVFurstDEInvestigatorsCHigh disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis20117078579110.1136/ard.2010.12863721288960 104.DanzaARuiz-IrastorzaGInfection risk"/>
  <result pre="SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19" exact="treatment" post="optionJ Med Virol202010.1002/jmv.2572932462770 109.CaoBWangYWenDLiuWWangJFanGRuanLSongBCaiYWeiMLiXXiaJChenNXiangJYuTBaiTXieXZhangLLiCYuanYChenHLiHHuangHTuSGongFLiuYWeiYDongCZhouFGuXXuJLiuZZhangYLiHShangLWangKLiKZhouXDongXQuZLuSHuXRuanSLuoSWuJPengLChengFPanLZouJJiaCWangJLiuXWangSWuXGeQHeJZhanHQiuFGuoLHuangCJakiTHaydenFGHorbyPWZhangDWangCA trial of lopinavirâ€&quot;ritonavir in adults"/>
  <result pre="Empyema Study GNonsteroidal anti-inflammatory drug without antibiotics for acute viral" exact="infection" post="increases the empyema risk in children: a matched caseâ€&quot;control"/>
  <result pre="community-acquired pneumonia in adult and pediatric patientsJ Clin Med201910.3390/jcm806078631163625 116.BatuEDGlucocorticoid" exact="treatment" post="in juvenile idiopathic arthritisRheumatol Int201939132710.1007/s00296-018-4168-030276425 117.ChanEDChanMMChanMMMarikPEUse of glucocorticoids in"/>
  <result pre="E, Chan J, Wong V, Hong Kong Hospital Authority SCGCorticosteroid" exact="treatment" post="of severe acute respiratory syndrome in Hong KongJ Infect200754283910.1016/j.jinf.2006.01.00516542729"/>
  <result pre="syndrome in Hong KongJ Infect200754283910.1016/j.jinf.2006.01.00516542729 121.AuyeungTWLeeJSLaiWKChoiCHLeeHKLeeJSLiPCLokKHNgYYWongWMYeungYMThe use of corticosteroid as" exact="treatment" post="in SARS was associated with adverse outcomes: a retrospective"/>
  <result pre="CC, for Taiwan Severe Influenza Research Consortium IImpact of corticosteroid" exact="treatment" post="on clinical outcomes of influenza-associated ARDS: a nationwide multicenter"/>
  <result pre="(COVID-19)Int J Rheum Dis202010.1111/1756-185X.1384232281213 128.GautretPLagierJCParolaPHoangVTMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHTHonoreSColsonPChabriereELa ScolaBRolainJMBrouquiPRaoultDHydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
  <result pre="trialInt J Antimicrob Agents202010.1016/j.ijantimicag.2020.10594932205204 129.MarmorMFKellnerULaiTYMellesRBMielerWFcollab: American Academy of ORecommendations on" exact="screening" post="for chloroquine and hydroxychloroquine retinopathy (2016 revision)Ophthalmology20161231386139410.1016/j.ophtha.2016.01.05826992838 130.O'LaughlinJPMehtaPHWongBCLife threatening"/>
  <result pre="arthritis-associated uveitisClin Rheumatol20203984785110.1007/s10067-019-04875-w31897953 134.SanchezGAMReinhardtARamseySWittkowskiHHashkesPJBerkunYSchalmSMuriasSDareJABrownDStoneDLGaoLKlausmeierTFoellDde JesusAAChapelleDCKimHDillSColbertRAFaillaLKostBO'BrienMReynoldsJCFolioLRCalvoKRPaulSMWeirNBrofferioASoldatosABiancottoACowenEWDigiovannaJJGadinaMLiptonAJHadiganCHollandSMFontanaJAlawadASBrownRJRotherKIHellerTBrooksKMKumarPBrooksSRWaldmanMSinghHKNickeleitVSilkMPrakashAJanesJMOzenSWakimPGBroganPAMaciasWLGoldbach-ManskyRJAK1/2 inhibition with baricitinib in the" exact="treatment" post="of autoinflammatory interferonopathiesJ Clin Invest20181283041305210.1172/JCI9881429649002 135.FavalliEGBiggioggeroMMaioliGCaporaliRBaricitinib for COVID-19: a"/>
  <result pre="for COVID-19: a suitable treatment?Lancet Infect Dis202010.1016/S1473-3099(20)30262-032251638 136.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAStebbingJBaricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 137.FensterlVSenGCInterferons and viral infectionsBioFactors200935142010.1002/biof.619319841"/>
  <result pre="150 patients from Wuhan ChinaIntensive Care Med.202010.1007/s00134-020-05991-x32253449 140.AlattarRIbrahimTBHShaarSHAbdallaSShukriKDaghfalJNKhatibMYAboukamarMAbukhattabMAlsoubHAAlmaslamaniMAOmraniASTocilizumab for the" exact="treatment" post="of severe coronavirus disease 2019J Med Virol202010.1002/jmv.2596432369191 141.AlzghariSKAcunaVSSupportive treatment"/>
  <result pre="the treatment of severe coronavirus disease 2019J Med Virol202010.1002/jmv.2596432369191 141.AlzghariSKAcunaVSSupportive" exact="treatment" post="with tocilizumab for COVID-19: a systematic reviewJ Clin Virol202012710438010.1016/j.jcv.2020.10438032353761"/>
  <result pre="L, Latronico N, Brescia International R, Training HUBTocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
  <result pre="Group of the Milan AAbsence of severe complications from SARS-CoV-2" exact="infection" post="in children with rheumatic diseases treated with biologic drugsJ"/>
 </snippets>
</snippetsTree>
